Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Cited by 117 Publications

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Nat Med, 2017, 23(12):1424-1435

PubMed: 29131160 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.215939

PubMed: 31289206 ( click the link to review the publication )

Theranostics, 2019, 9(7):1952-1964

PubMed: 31037149 ( click the link to review the publication )

J Physiol, 2019, 597(6):1627-1642

PubMed: 30488437 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(9):1108-1117

PubMed: 30785867 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2019, 9:80-86

PubMed: 30771616 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

J Immunol Methods, 2019, 464:22-30

PubMed: 30347189 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):85

PubMed: 29925404 ( click the link to review the publication )

Cell Mol Life Sci, 2018, 75(22):4223-4234

PubMed: 29955905 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):183

PubMed: 30081903 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):21

PubMed: 29776413 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1556-1567

PubMed: 29903769 ( click the link to review the publication )

Food Chem Toxicol, 2018, 119:464-478

PubMed: 29097117 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1285

PubMed: 30473665 ( click the link to review the publication )
Int J Oncol, 2018, 52(6):2061-2068

PubMed: 29620253 ( click the link to review the publication )

Cytokine, 2018, 111:209-215

PubMed: 30176559 ( click the link to review the publication )

Toxicol Lett, 2018, 296:39-47

PubMed: 30086328 ( click the link to review the publication )

FEBS Open Bio, 2018, 8(5):732-742

PubMed: 29744288 ( click the link to review the publication )

Nature, 2018, 563(7730):265-269

PubMed: 30401838 ( click the link to review the publication )

Sci Transl Med, 2017, 9(414)10

PubMed: 29093181 ( click the link to review the publication )

Blood, 2017, 129(11):e26-e37

PubMed: 28122742 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(23):7360-7374

PubMed: 28939749 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):118

PubMed: 28606127 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2387-2398

PubMed: 28775147 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Neoplasia, 2017, 19(4):354-363

PubMed: 28319809 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

Cancer Med, 2017, 6(4):809-818

PubMed: 28316141 ( click the link to review the publication )

Clin Res Hepatol Gastroenterol, 2017, 41(6):677-686

PubMed: 28578938 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:73-83

PubMed: 28123301 ( click the link to review the publication )

Eur J Haematol, 2017, 99(5):442-448

PubMed: 28881484 ( click the link to review the publication )

Arch Pharm Res, 2017, 40(2):197-203

PubMed: 27988882 ( click the link to review the publication )

Mol Vis, 2017, 23:823-831

PubMed: 29225458 ( click the link to review the publication )

Ther Drug Monit, 2017, 39(3):252-262

PubMed: 28490048 ( click the link to review the publication )

Leukemia, 2016, 30(6):1273-81

PubMed: 26987906 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Cancer Res, 2016, 76(12):3520-30

PubMed: 27197167 ( click the link to review the publication )
Int J Cancer, 2016, 139(10):2359-69

PubMed: 27434411 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

Breast Cancer Res, 2016, 18(1):80

PubMed: 27495374 ( click the link to review the publication )

J Infect Dis, 2016, 213(11):1767-76

PubMed: 26802142 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

BMC Cancer, 2016, 16:229

PubMed: 26984511 ( click the link to review the publication )

Oncol Lett, 2016, 12(5):3598-3608

PubMed: 27900042 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Sci Transl Med, 2015, 7(284):284ra57

PubMed: 25904741 ( click the link to review the publication )

Blood, 2015, 125(8):1282-91

PubMed: 25515960 ( click the link to review the publication )

Leukemia, 2015, 29(3):586-597

PubMed: 25134459 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: ( click the link to review the publication )

J Cell Sci, 2015, 128(2):251-65

PubMed: ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.021

PubMed: ( click the link to review the publication )

Clin Immunol, 2015, 157(2):205-215

PubMed: 25728491 ( click the link to review the publication )

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )

Pulm Pharmacol Ther, 2015, 10.1016/j.pupt.2015.03.001

PubMed: 25843005 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )
Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Leukemia, 2014, 28(10):2109-12

PubMed: 24919804 ( click the link to review the publication )

Cancer Lett, 2014, 344(1):90-100

PubMed: 24513268 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 14):3039-51

PubMed: 24928894 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(4):5838-51

PubMed: 24714091 ( click the link to review the publication )

J Pharm Biomed Anal, 2014, 94:125-31

PubMed: 24561338 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85485

PubMed: 24427313 ( click the link to review the publication )

Mol Biosyst, 2014, 10.1039/C4MB00224E

PubMed: 25099472 ( click the link to review the publication )

Leuk Lymphoma, 2014, 10.3109/10428194.2014.898759

PubMed: 24597981 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Graefes Arch Clin Exp Ophthalmol, 2014, 10.1007/s00417-014-2674-7

PubMed: 24874745 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

J Exp Med, 2013, 210(11):2205-21

PubMed: 24127489 ( click the link to review the publication )

J Exp Med, 2013, 210(12):2569-82

PubMed: 24190431 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5053-67

PubMed: 23900136 ( click the link to review the publication )

Cancer Lett, 2013, 340(1):43-50

PubMed: 23811285 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 145(2):531-8

PubMed: 23142123 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

Sci Rep, 2013, 3:2100

PubMed: 23812503 ( click the link to review the publication )
Blood, 2012, 119(21):4981-91

PubMed: 22411867 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(1):127-39

PubMed: 22090359 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(17):6584-10

PubMed: 22492965 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Br J Haematol, 2012, 157(4):510-4

PubMed: 22313359 ( click the link to review the publication )

J Virol, 2012, 86(16):8765-72

PubMed: 22696643 ( click the link to review the publication )

Angiogenesis, 2012, 15(1):33-45

PubMed: 22203239 ( click the link to review the publication )

Cancer Immunol Immun, 2012, 61(2):193-202

PubMed: 21874302 ( click the link to review the publication )

Invest New Drugs, 2012, 30(1):417-22

PubMed: 20953816 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )

Hematol Oncol, 2012, 31(3):156-63

PubMed: 23108877 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40853

PubMed: 22815843 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

J Liq Chromatogr R T, 2012, 2503-2510

PubMed: ( click the link to review the publication )

Cell Res, 2011, 21(7):1080-7

PubMed: 21423276 ( click the link to review the publication )

J Mol Biol, 2011, 411(2):474-85

PubMed: 21699901 ( click the link to review the publication )

J Virol, 2011, 85(5):2296-303

PubMed: 21177802 ( click the link to review the publication )

Cancer Prev Res , 2011, 4(8):1222-32

PubMed: 21546539 ( click the link to review the publication )

J Biol Chem, 2011, 286(16):13846-51

PubMed: 21343293 ( click the link to review the publication )

Exp Hematol, 2011, 39(8):859-65.e2

PubMed: 21689725 ( click the link to review the publication )

PLoS One, 2010, 5(11):e14143

PubMed: 21152443 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Targets

Abl ^[1] (Cell-free assay)	Src ^[1] (Cell-free assay)	c-Kit (D816V) ^[2] (Cell-free assay)	c-Kit (wt) ^[2] (Cell-free assay)
0.6 nM	0.8 nM	37 nM	79 nM

In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. ^[1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. ^[3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
M07ep210	M3HucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVy3NkBp	MoToSG1UVw>?	NHf1OGZKSzVyPUCuNFAxODdizszN	M{ezO\|E4QTV4MEiw
K562	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV\0[\|dpPzJiaB?=	M3;5XmROW09?	NWPP[XFsUUN3ME2wMlAxOSEQvF2=	NWXhclJJOTd7NU[wPFA>
M07e	M3u0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoO1O\|IhcA>?	MoruSG1UVw>?	MkLKTWM2OD1yLkCwNVIh\|ryP	NXz2bpF2OTd7NU[wPFA>
ALL3	NUXkZWVjS3m2b4TvfIlkKEG\|c3H5	MYewMlHPxE1?	NUXPeFN1PzJiaB?=	M2nQPWROW09?	Ml3sTWM2OD1yLkCwNFQh\|ryP	Mo\4NVk5QDl3NEC=
CML	MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYTOZY81OjBibXnu	M1u2VmROW09?	MkDmTWM2OD1yLkCwNUDPxE1?	M1X5SlE6OjF7MEG2
BA/F3	NEXqNW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUe3NkBp	NVvyN5RGTE2VTx?=	MlX1TWM2OD14LkW4PUDPxE1?	MmHpNlMxQDh4NES=
BA/F3	MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml7qO\|IhcA>?	NUXwWVhqTE2VTx?=	NVLNR3hvUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBOOzVzVDDteZRidnRid3n0bEBKSzVyIH;mJFAvODByOEROwG0>	MkDJNlMxQDh4NES=
BA/F3	NUfleHROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mm\QO\|IhcA>?	M1PFcGROW09?	NIiwTlZKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW\|c3nu[{B4cWymIIT5dIUhSmO{LVHicEB4cXSqIFnDOVAhd2ZiMD6wNFQ2\|ryP	NYDPPFV1OjNyOEi2OFQ>
BA/F3	M330Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXP6O5pxPzJiaB?=	MknQSG1UVw>?	MmPXTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy\|IHX4dJJme3OrbnegRoNzNUGkbDDUN\|E2USCvdYThcpQhf2m2aDDJR\|UxKG:oIEGuO\|E1\|ryP	MoHGNlMxQDh4NES=
BA/F3	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4rHV\|czKGh?	M2LaUGROW09?	Mn3BTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTjR6NmOgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNFnPxE1?	NEXrTYUzOzNyMUewNy=>
BA/F3	NUfqRo1DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXzs[VR{PzJiaB?=	M170OmROW09?	MoDHTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTJ3NVugcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwN\|LPxE1?	NHvwVmQzOzNyMUewNy=>
BA/F3	M{fwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnLmO\|IhcA>?	MULEUXNQ	MWfJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBIOjVyRTDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC1Ne69VQ>?	M2OxNFI{OzBzN{Cz
BA/F3	NYTTdZJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NU\EVJR1PzJiaB?=	NFPXSoZFVVOR	NUTBNVZHUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?=	MnLyNlM{ODF5MEO=
BA/F3	NUW1dm9LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoD3O\|IhcA>?	NG\ScFFFVVOR	M33xZmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV\|NUnWJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFE{\|ryP	NGexbI4zOzNyMUewNy=>
BA/F3	NHvqT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVfYNotpPzJiaB?=	NYq4UnE1TE2VTx?=	M2TCZmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViQlPSMWFDVCCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yMEG5{txO	NGjHdFUzOzNyMUewNy=>
BA/F3	NVnKXppLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2fjeVczKGh?	M{T4SGROW09?	Mn\TTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhYTJ3M1igcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNlPPxE1?	MmK3NlM{ODF5MEO=
BA/F3	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXe3NkBp	MV7EUXNQ	NHzwTodKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCWM{G1TUBufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIEOuOu69VQ>?	NEjkNHczOzNyMUewNy=>
BA/F3	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mn34O\|IhcA>?	Mn7VSG1UVw>?	Mlv4TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42\|ryP	MUeyN\|MxOTdyMx?=
T cell	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFjobWk4OiCq	Mk\0SG1UVw>?	MV;Jcohq[mm2czDhcpRqKEOGMz2gZY5lKGGwdHmgR2QzQC2rbnT1Z4VlKFRiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjByM988US=>	M33SeFE4OTV2NUGy
WiDr	M1jNRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1fTdFczKGh?	MVPEUXNQ	MoDrTWM2OD1yLkC1NkDPxE1?	MmmyNVU3OTV3MUK=
PC3	NH3oOHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYC3NkBp	NGfuOnpFVVOR	NIT3e\|JKSzVyPUCuNFA6PCEQvF2=	M3\neFE2PjF3NUGy
MDA-MB-231	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX23NkBp	NGjwRZBFVVOR	MWPJR\|UxRTBwMEGyJO69VQ>?	NWmxfIRVOTV4MUW1NVI>
Hs578T	NX\jRXJES3m2b4TvfIlkKEG\|c3H5		MYq3NkBp	MXnEUXNQ	NYHmWGRMT0l3ME2wMlA{KM7:TR?=	MUOyOFAyPTN{Nx?=
HMEC	NXjaNHp3S3m2b4TvfIlkKEG\|c3H5		M1nQ[lczKGh?	NHnoW5NFVVOR	M{Dx[mdKPTB;MT64JO69VQ>?	M3PYU\|I1ODF3M{K3
DU145	M3u4VGN6fG:2b4jpZ{BCe3OjeR?=		M2jtclczKGh?	MXnEUXNQ	NYC2N4FpT0l3ME2wMlE3KM7:TR?=	MWqyOFAyPTN{Nx?=
U251	NGnPSJFEgXSxdH;4bYMhSXO\|YYm=		NYeyRpJ4PzJiaB?=	NIXRNXdFVVOR	NH3NfXNIUTVyPUKuPFEh\|ryP	NU\LVYtEOjRyMUWzNlc>
NCI60	MXzDfZRwfG:6aXOgRZN{[Xl?		M4POeFczKGh?	M2K3N2ROW09?	MUXHTVUxRTVwNzFOwG0>	M4HrZVI1ODF3M{K3
MALME-3M	MlPLR5l1d3SxeHnjJGF{e2G7		NGHXfIM4OiCq	MUHEUXNQ	MYLHTVUxRTZwNkGg{txO	MkHsNlQxOTV\|Mke=
KM12	Mn75R5l1d3SxeHnjJGF{e2G7		NIfxSHE4OiCq	NV\ORlNzTE2VTx?=	MkLIS2k2OD15LkS0JO69VQ>?	MVeyOFAyPTN{Nx?=
SW620	M1jr[mN6fG:2b4jpZ{BCe3OjeR?=		MVi3NkBp	MlnqSG1UVw>?	MmTFS2k2OD16LkSzJO69VQ>?	M{jzdVI1ODF3M{K3
RXF 393NL	NXjWVWdmS3m2b4TvfIlkKEG\|c3H5		NWK5PXk{PCCmYYnz	MnzqSG1UVw>?	M3TPOGlEPTB;MD6wNlE4KM7:TR?=	MnnaNlMzPTNyN{S=
LXFA 983L	M{HrOWN6fG:2b4jpZ{BCe3OjeR?=		M1TxXVQh\GG7cx?=	NV7kWIlsTE2VTx?=	MWrJR\|UxRTBwMEW2OUDPxE1?	MlfiNlMzPTNyN{S=
PRXF DU145	NWXmSWJkS3m2b4TvfIlkKEG\|c3H5		MoHrOEBl[Xm\|	MYTEUXNQ	MX;JR\|UxRTBwME[yN{DPxE1?	M2P2[VI{OjV\|MEe0
PAXF 1657L	NXnteWU5S3m2b4TvfIlkKEG\|c3H5		MUC0JIRigXN?	MmCwSG1UVw>?	MWLJR\|UxRTBwMUKxJO69VQ>?	MWmyN\|I2OzB5NB?=
CXF 1103L	M3yzN2N6fG:2b4jpZ{BCe3OjeR?=		NFLafpY1KGSjeYO=	NFT0[pNFVVOR	NIrxRWdKSzVyPUSuN\|Yh\|ryP	MmrsNlMzPTNyN{S=
GXF251L	NHTkU3VEgXSxdH;4bYMhSXO\|YYm=		M{DiflQh\GG7cx?=	NFvCXXZFVVOR	NHKxPXNKSzVyPUKuNlUh\|ryP	MV:yN\|I2OzB5NB?=
NCI-H23	MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4rSOFczKGh?	NXjXW29OTE2VTx?=	MlzHTWM2OD1{LkK3JO69VQ>?	NUC0Rm1{OjN3MkGwNlA>
HCT116	NXz4NYF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV:3NkBp	MlfFSG1UVw>?	M4fIcWlEPTB;Mj6zJO69VQ>?	M2fQeVI{PTJzMEKw
MCF7	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUewfmlqPzJiaB?=	MYLEUXNQ	MU\JR\|UxRTJwNUeg{txO	NWLRdnl7OjN3MkGwNlA>
NCI-H460	M4PqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVG3NkBp	NYjlVHB1TE2VTx?=	NVPDbpV3UUN3ME24Mlk6KM7:TR?=	M3TOWlI{PTJzMEKw
DLD1	M1\BdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mn3XO\|IhcA>?	NYO5PG15TE2VTx?=	M3;weWlEPTB;ND62JO69VQ>?	M{XKfVI{PTZ5OU[w
NCI-H661	NYLnSHRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGfjOJk4OiCq	M2r1fGROW09?	MoKyTWM2OD15Lkig{txO	Ml2yNlM2Pjd7NkC=
A549	NVjkOXVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmDqO\|IhcA>?	MlTxSG1UVw>?	NIDYcohKSzVyPUiuNkDPxE1?	MXOyN\|U3Pzl4MB?=
U937	NH3NWWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGHlcVk4OiCq	NI\QUG1FVVOR	NVnTOHN5UUN3ME2xNk4zKM7:TR?=	MlPFNlM2Pjd7NkC=
HEK293	MXzGeY5kfGmxbjDBd5NigQ>?	MkXRNVDDqM7:TR?=		MonBSG1UVw>?	NITONGZKdmS3Y3XzJIJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6g[pVtdC2uZX7neIghUGm\|LYTh[4dm\CCPeYSxJItqdmG\|ZTDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IIfpeIghUUN3MDDv[kAxNjB4M988US=>	NXPaO2lUOjJ5N{C2NVA>
HUVEC	NXPEeldIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;TNE4yPcLizszN	Mnz0O\|IhcA>?	NFTq[o9FVVOR	NITOOWxKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIF1KDBwMUWgeW0>	NXS4VnBTOjJ6NUO5PVM>
HUVEC	MUTGeY5kfGmxbjDBd5NigQ>?	M33EZlE2yqEQvF2=	MUG3NkBp	NVrreopmTE2VTx?=	NV;kd29EUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO\|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1?	NH62RYQzOjh3M{m5Ny=>
Plasmodium falciparum	MmPPSpVv[3Srb36gRZN{[Xl?	NYPzRYdNOTEEoN88US=>	MXexOUBucW5?	M2O4NWROW09?	MnzsTY5pcWKrdIOgVIxie22xZHn1cUBn[WylaYDhdpVuKHC{b3zp[oVz[XSrb36gZpkhcW6qaXLpeIlv\yC2aHWgSpVv[3Srb36gc4YhWG[FRGDLNUBxem:2ZXnuJJdqfGhiSVO1NEBw\iBzLkG3{txO	M2jsVVI1PTVyM{Ow
PC3	NVO4WnNjTnWwY4Tpc44hSXO\|YYm=	M1nhfFAvOSEQvF2=	M3n1d\|UhcA>?	NXTIcnN{TE2VTx?=	NYDRV3RJUW6qaXLpeJMhcHWvYX6gVGM{KGOnbHygZYRp\XOrb36gZZQhOTByIH7N	MVuxPVQ3Ojl5NR?=
DU145	M4X4PWZ2dmO2aX;uJGF{e2G7	MXOwMlEh\|ryP	MUO1JIg>	NVvtTINUTE2VTx?=	MorRTY5pcWKrdIOgbJVu[W5iRGWxOFUh[2WubDDh[Ihme2mxbjDheEAyODBibl2=	M{PmeVE6PDZ{OUe1
PC3	MXjLbY5ie2ViQYPzZZk>	M{nze\|AvOSEQvF2=	NIS5d2I2KGh?	NXjtVIxmTE2VTx?=	NUfLdWdUUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR\|Mh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=>	NX7nfIVvOTl2NkK5O\|U>
DU145	NFjpeFVMcW6jc3WgRZN{[Xl?	MnG1NE4yKM7:TR?=	NUfMTIFEPSCq	M32yNGROW09?	NGPX[3RKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCVcnOgXVQyPiCuZY\lcEBifCBzMECgcm0>	MlLRNVk1PjJ7N{W=
PC3	M3jie2tqdmG\|ZTDBd5NigQ>?	M4rpelAvOSEQvF2=	MX[1JIg>	M1nG[WROW09?	MXnJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0>	NILjZ5oyQTR4Mkm3OS=>
DU145	NVrONm97U2mwYYPlJGF{e2G7	NXL2bJA6OC5zIN88US=>	MUO1JIg>	M1XrVmROW09?	NX7KWJl7UW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRlHLJHk2PzZxWUW3O{Bt\X[nbDDheEAyODBibl2=	NYTTW3k1OTl2NkK5O\|U>
Huh7	NITkOmNCdnSrdnnyZYwhSXO\|YYm=	NWjjb\|FJOi53IN88US=>	NHu2WJI1KGSjeYO=	M2P0RWROW09?	Ml3RTY5pcWKrdIOgeolz[Wxic4Dy[YFlKGmwIFTlcod2\SC4aYL1d{1qdm[nY4Tl[EBpfW2jbjDIeYg4KGOnbHzzJIF{e2W\|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWP	MnXBNVc{PjB4N{[=
C6/36	NH76SVhCdnSrdnnyZYwhSXO\|YYm=	MX[yMlUh\|ryP	M4PPPFQh\GG7cx?=	M33JNWROW09?	M2\MNGlvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQh[XOrYX6geIlo\XJibX;zdZVqfG9iQ{[vN\|Yh[2WubIOgZZN{\XO\|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1?	MkTSNVc{PjB4N{[=
U937	Mn73SpVv[3Srb36gRZN{[Xl?	Mn;UNUDPxE1?	MXexJIg>	MoHvSG1UVw>?	M1jVXnJm\HWlZYOgZoF{[WxiVF7GZYxxcGFicnXs[YF{\SCrbjDoeY1idiCXOUO3JINmdGy\|	M1T6b\|E4Pjh2MEm5
U937	Ml3vSpVv[3Srb36gRZN{[Xl?	NXPmVYNYOSEQvF2=	MVGxJIg>	NIrBbmxFVVOR	NWrLS2F4WmWmdXPld{BNWFNvaX7keYNm\CCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN?	MUCxO\|Y5PDB7OR?=
murine mast cell	MVjGeY5kfGmxbjDBd5NigQ>?	NEn6[ZIyKM7:TR?=	MlToNlQhcA>?	MVnEUXNQ	M{LuW2lvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP	M3XqPFE4Pjh2MEm5
BV-173	NXmydIh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTYfZF[UUN3ME2wMlAxODByMEGwPUDPxE1?	MVTTRW5ITVJ?
K-562	Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTBwMECwNFAxOjZ4IN88US=>	MWfTRW5ITVJ?
BL-70	M{DYV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmryTWM2OD1yLkCwNFAxODh{MjFOwG0>	MmHDV2FPT0WU
EM-2	NXXHOIZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWT2S4hKUUN3ME2wMlAxODByMUC4JO69VQ>?	NVv2Z3N3W0GQR1XS
LAMA-84	NVrScG1mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TZXGlEPTB;MD6wNFAxODN{MTFOwG0>	MULTRW5ITVJ?
MEG-01	MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{j3e2lEPTB;MD6wNFAxODl6IN88US=>	NFvqZVZUSU6JRWK=
EoL-1-cell	MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTBwMECwNFE{OSEQvF2=	MYDTRW5ITVJ?
CTV-1	Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjhcVRjUUN3ME2wMlAxODB2MESg{txO	NIGzXWNUSU6JRWK=
TE-15	M3X1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rIemlEPTB;MD6wNFU5QSEQvF2=	MXPTRW5ITVJ?
NOS-1	M{[2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnDXJlKSzVyPUCuNFA3OTNizszN	MkDTV2FPT0WU
D-336MG	NW\vOFBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHJTWM2OD1yLkCwOlMh\|ryP	NGDXR\|BUSU6JRWK=
LB1047-RCC	NXW0XppJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTBwMEC5PFkh\|ryP	M1GwdHNCVkeHUh?=
LB996-RCC	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3pXmhtUUN3ME2wMlAxQTlzIN88US=>	M3e2XHNCVkeHUh?=
SW982	MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlX1TWM2OD1yLkCxNVE2KM7:TR?=	MX7TRW5ITVJ?
TK10	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnSTWM2OD1yLkCxNVc1KM7:TR?=	M33iTnNCVkeHUh?=
A704	MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTBwMEG0PVEh\|ryP	Mki0V2FPT0WU
TE-8	NUT5PHh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HJd2lEPTB;MD6wNVU4PiEQvF2=	NYi3elhMW0GQR1XS
DOHH-2	NWTSRYJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvDTWM2OD1yLkCxO\|E6KM7:TR?=	MlfpV2FPT0WU
HOP-62	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnj1TWM2OD1yLkCxPFM1KM7:TR?=	M3zNVHNCVkeHUh?=
TE-12	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXGZ3E6UUN3ME2wMlAyQDZzIN88US=>	NYHNWG9bW0GQR1XS
KGN	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXyTWM2OD1yLkCxPVQzKM7:TR?=	MnWxV2FPT0WU
NCI-H1648	NFu3bJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrlTWM2OD1yLkCyNFEyKM7:TR?=	Mlq3V2FPT0WU
OS-RC-2	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXtOphKSzVyPUCuNFIxOyEQvF2=	NWmyZ5RmW0GQR1XS
GB-1	MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU[y[5VyUUN3ME2wMlAzOTV5IN88US=>	NYHGOoRIW0GQR1XS
RXF393	NWGzS\|BZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTBwMEKzOVch\|ryP	MnezV2FPT0WU
LC-2-ad	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXm3PFdNUUN3ME2wMlAzPTh4IN88US=>	NFLFRplUSU6JRWK=
KS-1	NHz3R3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIr2Z3NKSzVyPUCuNFI4OyEQvF2=	M4fQbHNCVkeHUh?=
ETK-1	NWjNeIpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nTUmlEPTB;MD6wNlg{OiEQvF2=	M2HhPHNCVkeHUh?=
SW954	M2niOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkThTWM2OD1yLkCyPVI4KM7:TR?=	NGXCUItUSU6JRWK=
Becker	MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXPPGJJUUN3ME2wMlA{ODB\|IN88US=>	MUXTRW5ITVJ?
MZ1-PC	M3TReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnqc2d{UUN3ME2wMlA{OTF7IN88US=>	NXXCOW9MW0GQR1XS
ES6	MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrCTWM2OD1yLkCzNVk{KM7:TR?=	Ml7pV2FPT0WU
KURAMOCHI	M3HlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTBwMEO0PFch\|ryP	MYrTRW5ITVJ?
CGTH-W-1	NGPLVnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3z3ZmlEPTB;MD6wN\|U1QCEQvF2=	NGnmSoZUSU6JRWK=
VA-ES-BJ	NECxNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTBwMEO5NFIh\|ryP	M3;Sc3NCVkeHUh?=
LXF-289	NV;rWmRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3Sw[GlEPTB;MD6wN\|k2PiEQvF2=	M4HCb3NCVkeHUh?=
MPP-89	NV\nUW5NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnXW4RKSzVyPUCuNFQxPDlizszN	MXfTRW5ITVJ?
SW872	NXrGenFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTBwMESxOlEh\|ryP	M2Dwe3NCVkeHUh?=
SNB75	M{XPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1OwOGlEPTB;MD6wOFQ{PSEQvF2=	MUTTRW5ITVJ?
PSN1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPkPVVKSzVyPUCuNFQ1PzRizszN	Mo\IV2FPT0WU
LB831-BLC	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTBwMES2NFkh\|ryP	NYSzd3R5W0GQR1XS
MFH-ino	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYi2U4lQUUN3ME2wMlA1PzJ2IN88US=>	NHnqbGJUSU6JRWK=
TGBC24TKB	M3TGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHNTWM2OD1yLkC0O\|YyKM7:TR?=	NHOydpVUSU6JRWK=
A388	MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TZS2lEPTB;MD6wOVA6PSEQvF2=	MWrTRW5ITVJ?
BB30-HNC	MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrDTWM2OD1yLkC1OFM4KM7:TR?=	NGnlc4VUSU6JRWK=
GI-ME-N	NXuwTWR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTBwME[xNVgh\|ryP	NYHXVmtYW0GQR1XS
TGBC1TKB	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTBwME[xOlQh\|ryP	M1vme3NCVkeHUh?=
TE-10	NF7NR2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGr4bW1KSzVyPUCuNFY{PTdizszN	MnfsV2FPT0WU
A498	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTBwMEeyPFQh\|ryP	M{LV[HNCVkeHUh?=
TE-11	M332ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\QO2lEPTB;MD6wO\|g2QCEQvF2=	NXXOTVRVW0GQR1XS
BB65-RCC	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHxTWM2OD1yLkC4NlI4KM7:TR?=	NWrIWYduW0GQR1XS
C2BBe1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYr4bJV{UUN3ME2wMlA5OzB6IN88US=>	NHvPWm1USU6JRWK=
NCI-H747	NWXXUZY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XBTGlEPTB;MD6wPFM3OiEQvF2=	M{PSZnNCVkeHUh?=
IST-MES1	MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4H4W2lEPTB;MD6wPFU2OiEQvF2=	MkjNV2FPT0WU
KALS-1	M17DW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWj3WmN{UUN3ME2wMlA6PDlizszN	NEL4OVdUSU6JRWK=
GCIY	MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvheYxKSzVyPUCuNFk3PTZizszN	NFLpcGVUSU6JRWK=
RL95-2	M1vlemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETRVHBKSzVyPUCuNVA{QCEQvF2=	MUXTRW5ITVJ?
TE-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfz[2lKSzVyPUCuNVA2PCEQvF2=	NF[yT\|lUSU6JRWK=
NCI-H1355	M2HVO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HKUmlEPTB;MD6xNVAzQCEQvF2=	MlfPV2FPT0WU
SW962	M4jN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHFTWM2OD1yLkGxNlkzKM7:TR?=	NIn1XmZUSU6JRWK=
KLE	M2PyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIq1WJBKSzVyPUCuNVE{OTdizszN	NFzQT4lUSU6JRWK=
MC116	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\Ie3Z5UUN3ME2wMlEyPDFizszN	MVXTRW5ITVJ?
NMC-G1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTBwMUG2NFYh\|ryP	M{W0XHNCVkeHUh?=
KU812	NXryNVNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonvTWM2OD1yLkGxPFg{KM7:TR?=	NGDOfHNUSU6JRWK=
COLO-829	NH7NS3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTBwMUKyNVMh\|ryP	NVXzc4ZZW0GQR1XS
NTERA-S-cl-D1	NWTEeHJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfuT2FjUUN3ME2wMlEzOjh\|IN88US=>	NVzhW4dkW0GQR1XS
IST-MEL1	M{m0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVS1SFBMUUN3ME2wMlE{PDVizszN	MknEV2FPT0WU
MLMA	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTBwMUSwN\|Ih\|ryP	M4H4XnNCVkeHUh?=
LS-123	NH\1VmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zFdGlEPTB;MD6xOFA3PCEQvF2=	NYTMSZFYW0GQR1XS
LB2518-MEL	NXXUSGRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HFVGlEPTB;MD6xOFE3OiEQvF2=	M1fPbnNCVkeHUh?=
NB69	NV7lbYlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDETWM2OD1yLkG0OFM3KM7:TR?=	NGm4Zo9USU6JRWK=
8-MG-BA	MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnkTWM2OD1yLkG1OFU5KM7:TR?=	NU\xe\|ViW0GQR1XS
K5	NWC2[IprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TrVWlEPTB;MD6xOlQ5QSEQvF2=	NFrXcHFUSU6JRWK=
KINGS-1	NIPCTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPaO3U3UUN3ME2wMlE3PjZ4IN88US=>	MnXBV2FPT0WU
SF268	NIHnVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTBwMUe0NFQh\|ryP	MYnTRW5ITVJ?
PF-382	NUjyfHd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfqTWM2OD1yLkG3Olc5KM7:TR?=	NWi5[3VrW0GQR1XS
SH-4	NULjWmh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVH4b\|h4UUN3ME2wMlE5PDF\|IN88US=>	MYjTRW5ITVJ?
NALM-6	M{C5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NED2NI1KSzVyPUCuNVkzQTVizszN	M3rwOHNCVkeHUh?=
CP66-MEL	NGrwSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWf4OGVMUUN3ME2wMlE6PTNzIN88US=>	NHnQdHBUSU6JRWK=
697	MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3vZ5dQUUN3ME2wMlE6QTh5IN88US=>	M3v3W3NCVkeHUh?=
CP67-MEL	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIKxfmZKSzVyPUCuNlA1QDhizszN	MnvUV2FPT0WU
DSH1	NIC5bFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHZTmVXUUN3ME2wMlI1ODBzIN88US=>	NGfRV4RUSU6JRWK=
HCE-4	M3zOdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;VTWM2OD1yLkK2OFM6KM7:TR?=	MYXTRW5ITVJ?
MZ2-MEL	M3jV[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjrTWM2OD1yLkK4OVM4KM7:TR?=	NVvuS41tW0GQR1XS
BL-41	NFrDc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXmx[np3UUN3ME2wMlI6OTJ\|IN88US=>	MUXTRW5ITVJ?
HUTU-80	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTBwM{G0NkDPxE1?	Ml:zV2FPT0WU
LOXIMVI	M{TTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHX[ZZKUUN3ME2wMlMyPTB\|IN88US=>	NFn1TYZUSU6JRWK=
no-10	MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIf3eodKSzVyPUCuN\|E6OzFizszN	NHSzPIVUSU6JRWK=
KARPAS-422	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTBwM{O5PVch\|ryP	NEj0eodUSU6JRWK=
SW684	NHizV\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTBwM{S5PEDPxE1?	MVTTRW5ITVJ?
SF126	M4XwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDlWWVQUUN3ME2wMlM2PDFizszN	NVjVNm5iW0GQR1XS
D-263MG	NUK5fmI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHYRmdKSzVyPUCuN\|YzOjRizszN	NYDOT5pwW0GQR1XS
OVCAR-4	NYj1NmExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HYW2lEPTB;MD6zO\|Q{OyEQvF2=	MnjlV2FPT0WU
BB49-HNC	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTBwM{i1PVkh\|ryP	NU\iNmxNW0GQR1XS
ONS-76	NFnIc\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DYSWlEPTB;MD60Nlk2OSEQvF2=	MVzTRW5ITVJ?
MZ7-mel	NEL4cWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTBwNEe5NVEh\|ryP	MYrTRW5ITVJ?
RCC10RGB	MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvxTWM2OD1yLkS5NVEh\|ryP	NEmwSY9USU6JRWK=
BOKU	MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;4[5RJUUN3ME2wMlQ6OTN\|IN88US=>	NIexWplUSU6JRWK=
no-11	NWS3cFllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWn0WWM1UUN3ME2wMlUxOjJ6IN88US=>	NFzQWJlUSU6JRWK=
IST-SL2	MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvyTWM2OD1yLkWwN\|AzKM7:TR?=	NEDNVWFUSU6JRWK=
RKO	NGLSOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;Td4NKSzVyPUCuOVI6PjZizszN	MWDTRW5ITVJ?
HT-144	M3G5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPOTGVOUUN3ME2wMlU{PjB7IN88US=>	MV;TRW5ITVJ?
NCI-H446	MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzPRpNKSzVyPUCuOlI4PiEQvF2=	MljmV2FPT0WU
QIMR-WIL	MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fuUGlEPTB;MD63NFYzQSEQvF2=	MoLoV2FPT0WU
MHH-PREB-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTBwN{S0Olkh\|ryP	M4DkPHNCVkeHUh?=
EW-16	M3PiW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTyTWM2OD1yLke2NVc5KM7:TR?=	NGexNXhUSU6JRWK=
EW-24	NIDsRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTBwN{ixOlUh\|ryP	M1nrdXNCVkeHUh?=
LB373-MEL-D	NWXYWJlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTBwOEK1NFgh\|ryP	NFXSW4NUSU6JRWK=
TE-9	M3rCdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XZ[WlEPTB;MD64O\|U{OiEQvF2=	MnH3V2FPT0WU
A3-KAW	MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTBwOUi0OVIh\|ryP	MknOV2FPT0WU
A101D	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlL1TWM2OD1zLkCzNFQ{KM7:TR?=	NXS2eGRqW0GQR1XS
OCUB-M	NH7QVFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTFwMES0NVIh\|ryP	NV7uUGdLW0GQR1XS
ES4	MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jlTGlEPTB;MT6wOVE1PSEQvF2=	M1nwbnNCVkeHUh?=
TE-6	M2jsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILrS3JKSzVyPUGuNlEzOjZizszN	M{nkS3NCVkeHUh?=
D-502MG	NIK0cFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTFwMkOzO\|Yh\|ryP	NIrKNZlUSU6JRWK=
KNS-42	NHLRT\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHSclNsUUN3ME2xMlI1PDF{IN88US=>	NEjuOoVUSU6JRWK=
SNU-C2B	NIPWW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnZSYJnUUN3ME2xMlMxPTh7IN88US=>	MkDFV2FPT0WU
NCI-H1838	NV7uXHl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzoTWM2OD1zLkOwO\|M{KM7:TR?=	MWnTRW5ITVJ?
NKM-1	M2T3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjKWXFLUUN3ME2xMlMxQDV7IN88US=>	MXPTRW5ITVJ?
GI-1	NYLkT\|NrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzRTWM2OD1zLkO2NlIh\|ryP	M3zoRnNCVkeHUh?=
NB5	M2rG[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPMW4k6UUN3ME2xMlM6QDJ5IN88US=>	NXjoe5BiW0GQR1XS
CAS-1	NFvzd\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYL6SlBrUUN3ME2xMlQxQTl{IN88US=>	MoDaV2FPT0WU
HCE-T	M3PTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjCTWM2OD1zLkW2O\|E1KM7:TR?=	NIDqZWtUSU6JRWK=
SBC-1	MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjTRlFKSzVyPUGuOVc6QDRizszN	NUHrb3NmW0GQR1XS
JiyoyeP-2003	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYm4TWlPUUN3ME2xMlc{PDZ4IN88US=>	MXrTRW5ITVJ?
TE-5	NW\YVoJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTFwN{mxN\|kh\|ryP	M1vx[XNCVkeHUh?=
CAN	NYTJRolKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTFwOEKyOVIh\|ryP	M3vpUHNCVkeHUh?=
SK-UT-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nqcGlEPTB;Mj6xOlY6OyEQvF2=	NXXOcI9rW0GQR1XS
JVM-2	NF[1SoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfEfnU1UUN3ME2yMlM3Ojh2IN88US=>	NXLkW2ZMW0GQR1XS
LB771-HNC	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnmd2JKSzVyPUKuOVc2PTFizszN	MXTTRW5ITVJ?
NCCIT	M4D5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jmdWlEPTB;Mj64OlYyPiEQvF2=	MXLTRW5ITVJ?
NCI-H2126	NYXqT\|BDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXW0[WwzUUN3ME2yMlg4PTV{IN88US=>	NYDrW4ZtW0GQR1XS
Calu-6	Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlK5TWM2OD1\|LkC1O\|QyKM7:TR?=	Ml3vV2FPT0WU
SK-LMS-1	NXnMXFVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTNwMUG4PFYh\|ryP	NVfKU3p4W0GQR1XS
ARH-77	NXrVNnQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFm1co1KSzVyPUOuOFY6OTVizszN	MYLTRW5ITVJ?
NB17	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTNwNkO4OFch\|ryP	NV3EdZJjW0GQR1XS
A253	MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HXdGlEPTB;Mz63N\|I1PiEQvF2=	NWDPcVlvW0GQR1XS
OPM-2	MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzXN3ZKSzVyPUSuNlc3QDVizszN	MkT6V2FPT0WU
MV-4-11	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLBenJKSzVyPUSuN\|Y1PTRizszN	NXjDTHNEW0GQR1XS
SR	MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTRwNEm5OVQh\|ryP	NXX1Z2RpW0GQR1XS
KG-1	M2jxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7ofWtKSzVyPUSuOlA5PDVizszN	MYfTRW5ITVJ?
OCI-AML2	NGmzXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHuzTolKSzVyPUWuPFYyPTRizszN	NX\tSlduW0GQR1XS
D-247MG	MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\lUohKSzVyPU[uNVI2OTlizszN	M1fhPXNCVkeHUh?=
DJM-1	Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrjVolVUUN3ME22MlQ5PTV6IN88US=>	MUXTRW5ITVJ?
RPMI-6666	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTtRlhKSzVyPUeuNlcxPjdizszN	MVTTRW5ITVJ?
KARPAS-45	MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTdwNUG2O\|Eh\|ryP	NXz4UlZ1W0GQR1XS
LP-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTdwNUS3PFIh\|ryP	NILNVXZUSU6JRWK=
RS4-11	NXXXW3FRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvHS25PUUN3ME23MlY2Pzh5IN88US=>	M3mwdnNCVkeHUh?=
DU-4475	M2\Gc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1GxWWlEPTB;OD6yNVY2OiEQvF2=	MnLKV2FPT0WU
MONO-MAC-6	M4Xad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\C[mNKSzVyPUiuNlcxPjZizszN	NHTrVGtUSU6JRWK=
NCI-SNU-16	NXzMdXNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjudHhmUUN3ME24MlU3OTJ6IN88US=>	NUHSb2M{W0GQR1XS
SJSA-1	NHXTNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HSbGlEPTB;OD63NlgxPSEQvF2=	NVnnV4kxW0GQR1XS
MMAC-SF	MoWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrlTWM2OD16Lke5N\|A4KM7:TR?=	MWjTRW5ITVJ?
SK-NEP-1	NF:5SHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRThwOEmxOVUh\|ryP	MlvxV2FPT0WU
J-RT3-T3-5	M{PuT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnlTlBKSzVyPUiuPVY2OjlizszN	MWHTRW5ITVJ?
SKM-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTlwMEG3N\|Qh\|ryP	NETld2NUSU6JRWK=
LB2241-RCC	NVv2XmtuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWq0cJZwUUN3ME25MlAzODF{IN88US=>	NUf0OoxiW0GQR1XS
SIG-M5	NEGyV\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTlwMEK0PVMh\|ryP	NF7ab2lUSU6JRWK=
EVSA-T	NEfGd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TTd2lEPTB;OT6yO\|c6OyEQvF2=	MkfvV2FPT0WU
GT3TKB	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX:3V4FHUUN3ME25MlM2PTR4IN88US=>	NHfYe5ZUSU6JRWK=
NB6	M3j6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DOeGlEPTB;OT65NlI2QSEQvF2=	MoTJV2FPT0WU
EHEB	NGTVfJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTFyLkC2OVYh\|ryP	M1jMWHNCVkeHUh?=
HEL	MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\pTWM2OD1zMD60O\|c3KM7:TR?=	NWXBTWZLW0GQR1XS
ALL-PO	Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUSyR5FKUUN3ME2xNE44QTN6IN88US=>	NU\UWGc2W0GQR1XS
TGW	M1\6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjMTWM2OD1zMT6yPFI5KM7:TR?=	NWHlZ2U1W0GQR1XS
BC-3	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHZTWM2OD1zMj6xNVM5KM7:TR?=	M4[3b3NCVkeHUh?=
IA-LM	NHrXSYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4izdmlEPTB;MUKuOFQ1PSEQvF2=	M37p[HNCVkeHUh?=
UACC-257	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3lSXhKSzVyPUGyMlkyQThizszN	M1LVR3NCVkeHUh?=
KP-N-YS	NE\PRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHVSGFKSzVyPUGyMlkzQDNizszN	NYLSdGk2W0GQR1XS
Raji	MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7WN5ZUUUN3ME2xN{44PDl5IN88US=>	M3HGbXNCVkeHUh?=
SF539	NV7UNYJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1Xqe2lEPTB;MUOuPFU2PyEQvF2=	Mn;iV2FPT0WU
DMS-153	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXqwU2hlUUN3ME2xOE4xODJ6IN88US=>	M2DEb3NCVkeHUh?=
L-540	NV[z[I5KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\uNIhvUUN3ME2xOU4xPjd{IN88US=>	M4\GfXNCVkeHUh?=
MN-60	M2DvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\2R2lEPTB;MUWuNVk4QSEQvF2=	NI\4e5pUSU6JRWK=
RPMI-8866	M{nxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTF5LkS0OVQh\|ryP	Mn;aV2FPT0WU
NCI-H510A	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXVWZVsUUN3ME2xPU4{QTd\|IN88US=>	M{TwXnNCVkeHUh?=
NB13	NYLDZ5hZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnf6TWM2OD1zOT60PFc4KM7:TR?=	MlvFV2FPT0WU
HAL-01	NHHPbGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\Nc4NHUUN3ME2xPU44PTR\|IN88US=>	NX\pVotmW0GQR1XS
NCI-H720	M3m4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTJyLkK3N\|Mh\|ryP	M3P2cXNCVkeHUh?=
REH	M2[zN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTJyLk[zOVch\|ryP	NH3o[nhUSU6JRWK=
KNS-81-FD	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfwTWM2OD1{Mz6xOFYh\|ryP	MYnTRW5ITVJ?
HC-1	NVr6Z3Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTJ2LkW1OVEh\|ryP	MXXTRW5ITVJ?
NCI-H2141	MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1na[GlEPTB;MkSuO\|c2PCEQvF2=	NIfoeo1USU6JRWK=
MOLT-4	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETVTVdKSzVyPUK2MlY4PTNizszN	MUfTRW5ITVJ?
OMC-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF[0dm1KSzVyPUK3MlE1OjJizszN	NGCz[VRUSU6JRWK=
LC-1F	MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rZSWlEPTB;MkeuN\|I1PSEQvF2=	NX72Xpd4W0GQR1XS
NCI-H1304	NHvoO\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTJ6LkG2Nlgh\|ryP	MXLTRW5ITVJ?
BC-1	MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDuTWM2OD1{OD62OVEh\|ryP	MUnTRW5ITVJ?
NCI-H64	NEXCbGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTOTWM2OD1{OT62NlU{KM7:TR?=	NV\WdJVHW0GQR1XS
MOLT-16	NH3hb\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHjTWM2OD1{OT62NlkzKM7:TR?=	NH\OWVNUSU6JRWK=
U-87-MG	M2W3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTNyLke2OkDPxE1?	NVXnRW57W0GQR1XS
GAK	MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTNzLkK2PFYh\|ryP	NV7OPGtuW0GQR1XS
ES8	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTN{LkGyOVIh\|ryP	M1nnNnNCVkeHUh?=
HCC1599	NWHpcFdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPLTWM2OD1\|Mj6zN\|I2KM7:TR?=	NGraTlhUSU6JRWK=
EB-3	Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkf4TWM2OD1\|ND6zNVE4KM7:TR?=	MmPLV2FPT0WU
HCC1187	MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXEU\|RNUUN3ME2zOU45ODV{IN88US=>	NV:0bXZtW0GQR1XS
SK-PN-DW	NWDrc5VwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTN4LkG5OFMh\|ryP	MVfTRW5ITVJ?
JVM-3	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\TTWM2OD1\|Nz6yN\|M5KM7:TR?=	MWLTRW5ITVJ?
HCC2157	MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDrTWM2OD1\|Nz65PVQ3KM7:TR?=	NFT4VYRUSU6JRWK=
A4-Fuk	NYDmPY05T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1KzOGlEPTB;M{iuNVAxQSEQvF2=	MVPTRW5ITVJ?
COR-L279	NWPFW3FIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHXTFRKSzVyPUSwMlI5PTFizszN	NGnEUJhUSU6JRWK=
DEL	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3ReHVuUUN3ME20NU46ODh4IN88US=>	NHv3TIlUSU6JRWK=
NCI-H1395	M1y1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DIWGlEPTB;NEKuNFE3OyEQvF2=	NVWz[2d1W0GQR1XS
MHH-NB-11	M1vQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml6wTWM2OD12Mz6wPFE5KM7:TR?=	NIfFe\|lUSU6JRWK=
NCI-H2107	Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mme5TWM2OD12Mz60PFQ3KM7:TR?=	NVj6VWExW0GQR1XS
NEC8	MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzEeWpzUUN3ME20OE4{OzZizszN	NGS5W2FUSU6JRWK=
COLO-684	NX\IeWRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NES2ZmpKSzVyPUS2MlIzPThizszN	M4iz[nNCVkeHUh?=
LS-411N	M1PGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfqOYNKSzVyPUS4MlQ4PDhizszN	MoHxV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); PubMed: 23049975 PLoS One Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition. p27 / p21; PubMed: 20145167 Clin Cancer Res Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading. p-FAK / p-STAT3; PubMed: 23721490 BMC Cancer The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive. cleaved caspase 3; PubMed: 20145167 Clin Cancer Res Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.	23049975 20145167 23721490
Growth inhibition assay	IC50; PubMed: 23721490 BMC Cancer 9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.	23721490
Immunofluorescence	SRC / Met; PubMed: 26517812 Oncotarget Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. F-actin / Actinin-4 / Paxillin; PubMed: 31053734 Nat Commun Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions. α-tubulin; PubMed: 26517812 Oncotarget Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.	26517812 31053734
ELISA	TNF-α; PubMed: 17684099 Proc Natl Acad Sci U S A U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate. E-selectin; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM). VCAM-1; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).	17684099 31110200

In vivo

Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. ^[3]

Protocol

Kinase Assay: ^[1]	+ Expand Kinase autophosphorylation assays: Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research: ^[1]	+ Expand Cell lines: Ba/F3 cell lines Concentrations: ~32 nM Incubation Time: 72 hours Method: Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I. (Only for Reference)
Animal Research: ^[3]	+ Expand Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC) Formulation: DMSO Dosages: 30 mg/kg Administration: Administered via i.p. (Only for Reference)

References

[4] Dargart JL, et al. Antiviral Res. 2012, 95(1), 49-56.

+ Expand

Solubility (25°C)

In vitro	DMSO	98 mg/mL (200.81 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dasatinib SDF

Molecular Weight	488.01
Formula	C₂₂H₂₆ClN₇O₂S
CAS No.	302962-49-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	BMS-354825

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03885830	Not yet recruiting	CML Chronic Phase\|CML (Chronic Myelogenous Leukemia\|CML - Philadelphia Chromosome\|Chronic Myeloid Leukemia\|Chronic Myeloid Leukemia Chronic Phase	UNC Lineberger Comprehensive Cancer Center	May 2019	--
NCT03885830	Not yet recruiting	CML Chronic Phase\|CML (Chronic Myelogenous Leukemia\|CML - Philadelphia Chromosome\|Chronic Myeloid Leukemia\|Chronic Myeloid Leukemia Chronic Phase	UNC Lineberger Comprehensive Cancer Center	May 2019	--
NCT03878524	Not yet recruiting	Breast Cancer\|Prostate Cancer\|Pancreatic Cancer\|Acute Myelogenous Leukemia	OHSU Knight Cancer Institute\|Oregon Health and Science University\|Prospect Creek Foundation	March 14 2019	Phase 1
NCT03878524	Not yet recruiting	Breast Cancer\|Prostate Cancer\|Pancreatic Cancer\|Acute Myelogenous Leukemia	OHSU Knight Cancer Institute\|Oregon Health and Science University\|Prospect Creek Foundation	March 14 2019	Phase 1
NCT03318770	Not yet recruiting	Acute Lymphoblastic Leukemia	Gruppo Italiano Malattie EMatologiche dell''Adulto	December 2018	--
NCT03318770	Not yet recruiting	Acute Lymphoblastic Leukemia	Gruppo Italiano Malattie EMatologiche dell''Adulto	December 2018	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
what’s the difference between S1021 and S7782? Which one is better for in vivo studies?
Answer:
Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).
Question 2:
Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?
Answer:
Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Pan Src Inhibitor

Saracatinib (AZD0530) : Pan-Src inhibitor, IC50=2.7-11 nM for c-Src/c-Yes/Fyn/Lyn/Blk/Fgr/Lck.
FDA-approved Src Inhibitor

Bosutinib (SKI-606) : Approved by FDA for Ph+ chronic myelogenous leukemia (CML).
Newest Src Inhibitor

PP1 : Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
Classic Src Inhibitor

KX2-391 : The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Related Src Products4

Dasatinib Monohydrate ^New

Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.
Bosutinib (SKI-606)

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.
KX2-391

KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.
PP1

PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
PP2

PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
WH-4-023

WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50s of 2 nM and 6 nM in cell-free assays, respectively. Exhibits >300-fold selectivity against p38α and KDR. Also potently inhibits SIK (IC50 values are 10, 22 and 60 nM for SIK 1, 2 and 3 respectively) and displays selectivity over a range of closely related kinases.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

Choose Your Country or Region

By Signaling Pathways

By product type

Dasatinib

Cited by 117 Publications

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dasatinib SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Dasatinib

Cited by 117 Publications

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dasatinib SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)